You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Ibrutinib

Showing 26 - 50 of 368
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

CNS Lymphoma, Secondary CNS Lymphoma Trial run by the National Cancer Institute (NCI) (TEDD-R, TEDDI-R, Ibrutinib)

Recruiting
  • Central Nervous System Lymphoma
  • Secondary Central Nervous System Lymphoma
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Diffuse Large B Cell Lymphoma Trial in Berlin (Ibrutinib and Bortezomib + R-CHOP)

Active, not recruiting
  • Diffuse Large B Cell Lymphoma
  • Ibrutinib and Bortezomib + R-CHOP
  • Berlin, Germany
    Charité - Universitätsmedizin Berlin, Hematology, Oncology and T
Aug 10, 2022

Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +5 more
  • Ibrutinib
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 12, 2022

Prostate Cancer Trial in San Francisco, Saint Louis (Ibrutinib, Blood samples for PSA and immune assays, Radical prostatectomy)

Recruiting
  • Prostate Cancer
  • Ibrutinib
  • +2 more
  • San Francisco, California
  • +1 more
Aug 15, 2022

Breast Tumors, Malignant Tumor of Breast Trial in Dallas (Trastuzumab, Ibrutinib 560 mg, Ibrutinib 840 mg)

Recruiting
  • Breast Neoplasms
  • Malignant Neoplasm of Breast
  • Dallas, Texas
    10 sites incl TX, WA, VA, and NV
May 16, 2022

Waldenstrom's Macroglobulinemia Trial in Boston (Ulocuplumab, Ibrutinib)

Active, not recruiting
  • Waldenstrom's Macroglobulinemia
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jun 20, 2022

Chronic Lymphocytic Leukemia (CLL) Trial in Boston (Ibrutinib, Copanlisib, Acalabrutinib)

Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Ibrutinib
  • +2 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
May 13, 2022

Lymphoma, Mantle-Cell, Lymphoma, Lymphoproliferative Disorders Trial (Zilovertamab, Ibrutinib, Placebo)

Not yet recruiting
  • Lymphoma, Mantle-Cell
  • +7 more
  • (no location specified)
Jun 21, 2022

Chronic Graft-versus-host-disease Trial in Monterrey (Low-dose ibrutinib)

Recruiting
  • Chronic Graft-versus-host-disease
  • Low-dose ibrutinib
  • Monterrey, Nuevo Leon, Mexico
    Hospital Universitario Dr. José Eleuterio González
Apr 21, 2022

Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma Trial in New York (Ibrutinib, Pembrolizumab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Mantle Cell Lymphoma
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Aug 22, 2022

Chronic Lymphocytic Leukemia Trial in Spain (Ibrutinib 140 MG Oral Capsule [Imbruvica])

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Ibrutinib 140 MG Oral Capsule [Imbruvica]
  • Palma De Mallorca, Illes Balears, Spain
  • +19 more
Sep 15, 2022

Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston (drug,

Active, not recruiting
  • Prolymphocytic Leukemia
  • +2 more
  • Ibrutinib
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 7, 2022

Lymphoma, Non-Hodgkin Lymphoma, DLBCL Trial run by the National Cancer Institute (NCI) (Venetoclax, Ibrutinib, Prednisone)

Recruiting
  • Lymphoma
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 20, 2022

Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell Trial in Whittier (Pirtobrutinib, Ibrutinib)

Recruiting
  • Chronic Lymphocytic Leukemia
  • +3 more
  • Whittier, California
    Innovative Clinical Research Institute
Aug 8, 2022

Waldenstrom Macroglobulinemia Trial in Japan (Ibrutinib, Rituximab)

Active, not recruiting
Has Results
  • Waldenstrom Macroglobulinemia
  • Chiba, Japan
  • +8 more
Jan 27, 2023

Mantle-Cell Lymphoma Trial in United States (Ixazomib, Ibrutinib)

Active, not recruiting
  • Mantle-Cell Lymphoma
  • Atlanta, Georgia
  • +13 more
Nov 17, 2022

Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma Trial in

Recruiting
  • Ann Arbor Stage II Follicular Lymphoma
  • +5 more
  • Ibrutinib
  • +2 more
  • Fresno, California
  • +2 more
Jan 24, 2023

Chronic Lymphocytic Leukemia Trial in Milano (Ibrutinib and obinutuzumab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Ibrutinib and obinutuzumab
  • Milano, MI, Italy
    Strategic Research Program on CLL
Apr 2, 2022

Leukemia, Lymphocytic, Chronic Trial in Germany (ibrutinib, obinutuzumab, venetoclax)

Completed
  • Leukemia, Lymphocytic, Chronic
  • ibrutinib
  • +2 more
  • Dresden, Germany
  • +10 more
Jan 13, 2023

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin Trial in Worldwide (JNJ-67856633, Ibrutinib)

Active, not recruiting
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Lymphoma, Non-Hodgkin
  • Copenhagen, Denmark
  • +9 more
Jan 27, 2023

CLL/SLL Trial in Beijing (orelabrutinib)

Recruiting
  • CLL/SLL
  • Beijing, Beijing, China
  • +1 more
Aug 5, 2022

Colon Cancer, Colorectal Cancer, Colorectal Carcinoma Trial in Tampa (Pembrolizumab, Ibrutinib)

Completed
Has Results
  • Colon Cancer
  • +3 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Jun 1, 2022

Mantle Cell Lymphoma Trial in Houston (Acalabrutinib)

Recruiting
  • Mantle Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Aug 22, 2022

Refractory Follicular Lymphoma, Relapsed Follicular Lymphoma Trial in Washington, Hackensack, Seattle (Ibrutinib, Venetoclax)

Recruiting
  • Refractory Follicular Lymphoma
  • Relapsed Follicular Lymphoma
  • Washington, District of Columbia
  • +2 more
Jul 6, 2022

Waldenstrom Macroglobulinemia, MYD88 Gene Mutation Trial in Boston (IBRUTINIB, Venetoclax)

Active, not recruiting
  • Waldenstrom Macroglobulinemia
  • MYD88 Gene Mutation
  • Boston, Massachusetts
  • +1 more
Apr 1, 2022